SAN DIEGO --(BUSINESS WIRE)--Oct. 6, 2015-- Illumina, Inc. (NASDAQ:ILMN) today announced it has expanded the rights of use for the HiSeq X Sequencing System to allow customers to perform whole-genome sequencing of non-human species. The updated rights of use will take effect immediately for existing customers of the HiSeq X Ten and HiSeq X Five, and will apply to all new customers of the sequencing systems.
Driven by the world's first $1,000 human genome and significant demand for population-scale sequencing, more than 125,000 human whole-genome samples have been sequenced on the platform since its release in January 2014 . The updated rights of use will allow for market expansion and population-scale sequencing of non-human species in a variety of markets, including plants and livestock in agricultural research and model organisms in pharmaceutical research. Previously, it has been cost prohibitive to sequence non-human genomes at high coverage.
"The Wellcome Trust Sanger Institute is excited to be able to sequence non-human genomes on the HiSeq X Platform," said Emma Millican, Director of Scientific Operations. "Understanding the genetics and biological processes of non-human organisms is a major area of focus for the Sanger Institute and this update will enable large-scale whole-genome sequencing projects, important for public health, that otherwise would not have happened. The Sanger Institute plans to extend whole-genome population sequencing to many more medically relevant organisms in the future."
"Market adoption of the HiSeq X system for population-scale studies has exceeded our expectations and we are excited for new and existing customers to take their research to new heights," said Francis deSouza, President of Illumina . "With its ultrahigh throughput and unprecedented price point per genome, the HiSeq X system now provides customers with an opportunity to reshape the economics and scale of whole-genome sequencing beyond the human species."
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission , including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151006005360/en/
This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20151006005360/en/
Source: Illumina, Inc.
Rebecca Chambers, 858-255-5243
Tina Amirkiai, 858-882-6822